Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients

por Jia, Jun, Yu, Jing, Sun, Zhiwei, Yang, Ying, Liu, Chuanling, Xiao, Yanjie, Zhang, Xiaodong
Publicado 2021

Prognosis impact of clinical characteristics in patients with inoperable esophageal squamous cell carcinoma

por Yang, Ying, Jia, Jun, Sun, Zhiwei, Du, Feng, Yu, Jing, Liu, Chuanling, Xiao, Yanjie, Zhang, Xiaodong
Publicado 2017

Association Between Multiple Lines of Active Therapy and Prognosis in Esophageal Squamous Cell Carcinoma

por Yang, Ying, Jia, Jun, Sun, Zhiwei, Liu, Chuanling, Xiao, Yanjie, Yu, Jing, Du, Feng, Zhang, Xiaodong
Publicado 2020

Clinical significance of serum tumor markers for advanced gastric cancer with the first-line chemotherapy

por Sun, Zhiwei, Jia, Jun, Du, Feng, Yang, Ying, Liu, Chuanling, Xiao, Yanjie, Yu, Jing, Zhang, Xiaodong
Publicado 2019

Nimotuzumab Plus Paclitaxel and Cisplatin as a 1(st)-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study

por Zhang, Xiaodong, Jia, Jun, Lu, Ming, Wang, Xicheng, Gong, Jifang, Li, Jie, Li, Jian, Li, Yan, Zhang, Xiaotian, Lu, Zhihao, Zhou, Jun, Yu, Jing, Sun, Zhiwei, Yang, Ying, Liu, Chuanling, Xiao, Yanjie, Shen, Lin
Publicado 2019